These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 28385506)

  • 21. Novel potent and selective pyrazolylpyrimidine-based SYK inhibitors.
    Barlaam B; Boiko S; Boyd S; Dry H; Gingipalli L; Ikeda T; Johnson T; Kawatkar S; Lorthioir O; Pike A; Pollard H; Read J; Su Q; Wang H; Wang H; Wang L; Wang P; Edmondson SD
    Bioorg Med Chem Lett; 2020 Nov; 30(22):127523. PubMed ID: 32877741
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Rapid Access to Kinase Inhibitor Pharmacophores by Regioselective C-H Arylation of Thieno[2,3-
    Yamada S; Flesch KN; Murakami K; Itami K
    Org Lett; 2020 Feb; 22(4):1547-1551. PubMed ID: 32009412
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Imidazo[1,2-c]pyrimidin-5(6H)-one inhibitors of CDK2: Synthesis, kinase inhibition and co-crystal structure.
    Jansa J; Jorda R; Škerlová J; Pachl P; Peřina M; Řezníčková E; Heger T; Gucký T; Řezáčová P; Lyčka A; Kryštof V
    Eur J Med Chem; 2021 Apr; 216():113309. PubMed ID: 33711765
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Discovery of potent 1H-imidazo[4,5-b]pyridine-based c-Met kinase inhibitors via mechanism-directed structural optimization.
    An XD; Liu H; Xu ZL; Jin Y; Peng X; Yao YM; Geng M; Long YQ
    Bioorg Med Chem Lett; 2015 Feb; 25(3):708-16. PubMed ID: 25529740
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Discovery of potent and selective thienopyrimidine inhibitors of Aurora kinases.
    McClellan WJ; Dai Y; Abad-Zapatero C; Albert DH; Bouska JJ; Glaser KB; Magoc TJ; Marcotte PA; Osterling DJ; Stewart KD; Davidsen SK; Michaelides MR
    Bioorg Med Chem Lett; 2011 Sep; 21(18):5620-4. PubMed ID: 21778056
    [TBL] [Abstract][Full Text] [Related]  

  • 26. 3-aminopyrazolopyrazine derivatives as spleen tyrosine kinase inhibitors.
    Shen J; Li X; Zhang Z; Luo J; Long H; Tu Z; Zhou X; Ding K; Lu X
    Chem Biol Drug Des; 2016 Nov; 88(5):690-698. PubMed ID: 27264434
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Highly potent and selective pyrazolylpyrimidines as Syk kinase inhibitors.
    Choi JS; Hwang HJ; Kim SW; Lee BI; Lee J; Song HJ; Koh JS; Kim JH; Lee PH
    Bioorg Med Chem Lett; 2015 Oct; 25(20):4441-6. PubMed ID: 26384287
    [TBL] [Abstract][Full Text] [Related]  

  • 28. 4-([1,2,4]Triazolo[1,5-a]pyridin-6-yl)-5(3)-(6-methylpyridin-2-yl)imidazole and -pyrazole derivatives as potent and selective inhibitors of transforming growth factor-β type I receptor kinase.
    Jin CH; Krishnaiah M; Sreenu D; Subrahmanyam VB; Park HJ; Park SJ; Sheen YY; Kim DK
    Bioorg Med Chem; 2014 May; 22(9):2724-32. PubMed ID: 24704197
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Discovery and initial SAR of pyrimidin-4-yl-1H-imidazole derivatives with antiproliferative activity against melanoma cell lines.
    Lee J; Kim H; Yu H; Chung JY; Oh CH; Yoo KH; Sim T; Hah JM
    Bioorg Med Chem Lett; 2010 Mar; 20(5):1573-7. PubMed ID: 20149658
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Discovery of pyrazolo[1,5-a]pyrimidine-based CHK1 inhibitors: a template-based approach--part 1.
    Dwyer MP; Paruch K; Labroli M; Alvarez C; Keertikar KM; Poker C; Rossman R; Fischmann TO; Duca JS; Madison V; Parry D; Davis N; Seghezzi W; Wiswell D; Guzi TJ
    Bioorg Med Chem Lett; 2011 Jan; 21(1):467-70. PubMed ID: 21094608
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Structure-based design, synthesis, and evaluation of imidazo[1,2-b]pyridazine and imidazo[1,2-a]pyridine derivatives as novel dual c-Met and VEGFR2 kinase inhibitors.
    Matsumoto S; Miyamoto N; Hirayama T; Oki H; Okada K; Tawada M; Iwata H; Nakamura K; Yamasaki S; Miki H; Hori A; Imamura S
    Bioorg Med Chem; 2013 Dec; 21(24):7686-98. PubMed ID: 24216091
    [TBL] [Abstract][Full Text] [Related]  

  • 32. 2,4-Diaminopyrimidine MK2 inhibitors. Part I: Observation of an unexpected inhibitor binding mode.
    Argiriadi MA; Ericsson AM; Harris CM; Banach DL; Borhani DW; Calderwood DJ; Demers MD; Dimauro J; Dixon RW; Hardman J; Kwak S; Li B; Mankovich JA; Marcotte D; Mullen KD; Ni B; Pietras M; Sadhukhan R; Sousa S; Tomlinson MJ; Wang L; Xiang T; Talanian RV
    Bioorg Med Chem Lett; 2010 Jan; 20(1):330-3. PubMed ID: 19919896
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Potent Pyrimidine and Pyrrolopyrimidine Inhibitors of Testis-Specific Serine/Threonine Kinase 2 (TSSK2).
    Hawkinson JE; Sinville R; Mudaliar D; Shetty J; Ward T; Herr JC; Georg GI
    ChemMedChem; 2017 Nov; 12(22):1857-1865. PubMed ID: 28952188
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Imidazopyridine derivatives as potent and selective Polo-like kinase (PLK) inhibitors.
    Sato Y; Onozaki Y; Sugimoto T; Kurihara H; Kamijo K; Kadowaki C; Tsujino T; Watanabe A; Otsuki S; Mitsuya M; Iida M; Haze K; Machida T; Nakatsuru Y; Komatani H; Kotani H; Iwasawa Y
    Bioorg Med Chem Lett; 2009 Aug; 19(16):4673-8. PubMed ID: 19589677
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Discovery of 5-(2-(phenylamino)pyrimidin-4-yl)thiazol-2(3H)-one derivatives as potent Mnk2 inhibitors: synthesis, SAR analysis and biological evaluation.
    Diab S; Teo T; Kumarasiri M; Li P; Yu M; Lam F; Basnet SK; Sykes MJ; Albrecht H; Milne R; Wang S
    ChemMedChem; 2014 May; 9(5):962-72. PubMed ID: 24677692
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Dihydrobenzo[4,5]imidazo[1,2-a]pyrimidine-4-ones as a new class of CK2 inhibitors.
    Protopopov MV; Ostrynska OV; Starosyla SA; Vodolazhenko MA; Sirko SM; Gorobets NY; Bdzhola V; Desenko SM; Yarmoluk SM
    Mol Divers; 2018 Nov; 22(4):991-998. PubMed ID: 29845490
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Synthesis and evaluation of alkenyl indazoles as selective Aurora kinase inhibitors.
    Blanchard S; William AD; Lee AC; Poulsen A; Teo EL; Deng W; Tu N; Tan E; Goh KL; Ong WC; Ng CP; Goh KC; Bonday Z; Sun ET
    Bioorg Med Chem Lett; 2010 Apr; 20(8):2443-7. PubMed ID: 20338758
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Design, Synthesis and Bioactivity Evaluation of 4,6-Disubstituted Pyrido[3,2-
    Xing K; Zhang J; Han Y; Tong T; Liu D; Zhao L
    Molecules; 2020 Sep; 25(18):. PubMed ID: 32967084
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Discovery of TAK-659 an orally available investigational inhibitor of Spleen Tyrosine Kinase (SYK).
    Lam B; Arikawa Y; Cramlett J; Dong Q; de Jong R; Feher V; Grimshaw CE; Farrell PJ; Hoffman ID; Jennings A; Jones B; Matuszkiewicz J; Miura J; Miyake H; Natala SR; Shi L; Takahashi M; Taylor E; Wyrick C; Yano J; Zalevsky J; Nie Z
    Bioorg Med Chem Lett; 2016 Dec; 26(24):5947-5950. PubMed ID: 27839918
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Application of Pd-Catalyzed Cross-Coupling Reactions in the Synthesis of 5,5-Dimethyl-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazoles that Inhibit ALK5 Kinase.
    Tenora L; Galeta J; Řezníčková E; Kryštof V; Potáček M
    J Org Chem; 2016 Dec; 81(23):11841-11856. PubMed ID: 27934472
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.